AU2001289068A1 - Antisense modulation of caspase 2 expression - Google Patents
Antisense modulation of caspase 2 expressionInfo
- Publication number
- AU2001289068A1 AU2001289068A1 AU2001289068A AU8906801A AU2001289068A1 AU 2001289068 A1 AU2001289068 A1 AU 2001289068A1 AU 2001289068 A AU2001289068 A AU 2001289068A AU 8906801 A AU8906801 A AU 8906801A AU 2001289068 A1 AU2001289068 A1 AU 2001289068A1
- Authority
- AU
- Australia
- Prior art keywords
- caspase
- expression
- antisense modulation
- antisense
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004046 Caspase-2 Human genes 0.000 title 1
- 108090000552 Caspase-2 Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22055—Caspase-2 (3.4.22.55)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66701800A | 2000-09-20 | 2000-09-20 | |
| US09667018 | 2000-09-20 | ||
| PCT/US2001/028631 WO2002024720A1 (en) | 2000-09-20 | 2001-09-14 | Antisense modulation of caspase 2 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001289068A1 true AU2001289068A1 (en) | 2002-04-02 |
Family
ID=24676465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001289068A Abandoned AU2001289068A1 (en) | 2000-09-20 | 2001-09-14 | Antisense modulation of caspase 2 expression |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001289068A1 (en) |
| WO (1) | WO2002024720A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2855054B1 (en) * | 2003-05-22 | 2005-07-08 | Theraptosis | MEANS FOR BLOCKING OR DELAYING IN VITRO CELL DEATH |
| JP4991297B2 (en) * | 2003-05-22 | 2012-08-01 | キエジ ファルマチェウティチ エッセ・ピ・ア | Means for preventing and treating cell death and their biological applications |
| EP1740614A2 (en) | 2004-04-30 | 2007-01-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
| JP2010507387A (en) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US8431692B2 (en) | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| WO2009155662A1 (en) * | 2008-06-27 | 2009-12-30 | Medvet Science Pty Ltd | A tumour suppressor protein, caspase-2 |
| NZ591391A (en) | 2008-10-22 | 2012-10-26 | Quark Pharmaceuticals Inc | Non-invasive methods for treating eye disorders using a topical oligonucleotide composition |
| US20140323549A1 (en) * | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087160A (en) * | 1993-06-24 | 2000-07-11 | The General Hospital Corporation | Programmed cell death genes and proteins |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2001
- 2001-09-14 WO PCT/US2001/028631 patent/WO2002024720A1/en not_active Ceased
- 2001-09-14 AU AU2001289068A patent/AU2001289068A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002024720A1 (en) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001229363A1 (en) | Antisense modulation of caspase 3 expression | |
| AU2002213002A1 (en) | Antisense inhibition of caspase 6 expression | |
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU5239399A (en) | Antisense modulation of g-alpha-13 expression | |
| AU5587499A (en) | Antisense modulation of g-alpha-16 expression | |
| AU4576999A (en) | Antisense modulation of tnfr1 expression | |
| AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
| AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
| AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
| AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
| AU4325199A (en) | Antisense modulation of g-alpha-11 expression | |
| AU2001289046A1 (en) | Antisense modulation of her-2 expression | |
| AU2002213467A8 (en) | Modulation of ccr4 function | |
| AU6692701A (en) | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides | |
| AU2001239971A1 (en) | Antisense modulation of parp expression | |
| AU5222899A (en) | Antisense modulation of inhibitor-kappa b kinase-alpha expression | |
| AU5321199A (en) | Antisense modulation of inhibitor-kappa b kinase-beta expression | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU6115400A (en) | Antisense modulation of mekk5 expression | |
| AU2001227848A1 (en) | Antisense modulation of caspase 8 expression | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2002226064A1 (en) | Antisense modulation of talin expression | |
| AU2001289068A1 (en) | Antisense modulation of caspase 2 expression | |
| AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
| AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression |